Abstract
Despite significant improvements in early detection and refinements of therapeutic protocols over the last several decades, cancer remains one of the leading causes of death in North America. In particular, treatment of metastatic cancers is a highly desirable and yet still elusive goal of the oncologist. One strategy which holds promise is the use of self replicating viral strains with the ability to specifically kill tumour but not normal cells. These so-called “oncolytic viruses” are in general, attenuated for growth in normal cells but are able to exploit tumour specific, genetic defects to gain a growth advantage. In this review, we will discuss the virus:host cell interactions which help form the niche occupied by oncolytic viruses. The current and potential clinical applications / limitations will be discussed for oncolytic viruses from the herpesvirus, adenoviruses, picornavirus, rhabdovirus, and paramyxovirus families.
Keywords: Oncolytic Viruses, Tumour Hunters, Paramyxoviruses, Fibre Knob
Current Gene Therapy
Title: Oncolytic Viruses: Programmable Tumour Hunters
Volume: 2 Issue: 2
Author(s): J. C. Bell, K. A. Garson, B. D. Lichty and F. D. Stojdl
Affiliation:
Keywords: Oncolytic Viruses, Tumour Hunters, Paramyxoviruses, Fibre Knob
Abstract: Despite significant improvements in early detection and refinements of therapeutic protocols over the last several decades, cancer remains one of the leading causes of death in North America. In particular, treatment of metastatic cancers is a highly desirable and yet still elusive goal of the oncologist. One strategy which holds promise is the use of self replicating viral strains with the ability to specifically kill tumour but not normal cells. These so-called “oncolytic viruses” are in general, attenuated for growth in normal cells but are able to exploit tumour specific, genetic defects to gain a growth advantage. In this review, we will discuss the virus:host cell interactions which help form the niche occupied by oncolytic viruses. The current and potential clinical applications / limitations will be discussed for oncolytic viruses from the herpesvirus, adenoviruses, picornavirus, rhabdovirus, and paramyxovirus families.
Export Options
About this article
Cite this article as:
Bell C. J., Garson A. K., Lichty D. B. and Stojdl D. F., Oncolytic Viruses: Programmable Tumour Hunters, Current Gene Therapy 2002; 2 (2) . https://dx.doi.org/10.2174/1566523024605582
DOI https://dx.doi.org/10.2174/1566523024605582 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs
Current Pharmaceutical Design Probiotics and Different Efficacy, How it can be Managed?
Current Drug Therapy MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer
Recent Patents on Anti-Cancer Drug Discovery An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science Expression, Regulation, and Role of an Oligopeptide Transporter: PEPT1 in Tumors
Current Medicinal Chemistry Controversies of Androgen Ablation Therapy for Metastatic Prostate Cancer
Current Pharmaceutical Design Bladder Injury During Cesarean Delivery
Current Women`s Health Reviews Bioavailability Challenges Associated with Development of Anti-Cancer Phenolics
Mini-Reviews in Medicinal Chemistry Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice
Current Radiopharmaceuticals Cytochrome P450 Gene Polymorphism and Cancer
Current Drug Metabolism Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Aqueous Extracts of Selected Potentilla Species Modulate Biological Activity of Human Normal Colon Cells
Current Drug Targets Targeting Epigenome As An Innovative Pharmacological Strategy For Castration-resistant Prostate Cancer
Clinical Cancer Drugs In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry β-Glucuronidase Inhibitory Studies on Coumarin Derivatives
Medicinal Chemistry Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Current Cancer Drug Targets